Kornimate/medical-research-clean huggingface dataset:
cad-eye system for the detection of neoplastic lesions in patients with lynch syndrome

Conditions: Lynch Syndrome

Summary: lynch syndrome (ls) is the most common genetic predisposition syndrome for colorectal cancer (crc), responsible for around 2-4% of cancers. it is characterized by a pathogenic germline mutation in one of the dna mismatch repair genes (path_mmr) mlh1, msh2, msh6, pms2 or a deletion in the 3' region of the epcam gene. patients followed up for ls are at high risk of developing crc at an early age, and have a high cumulative crc risk. in this context, crc screening by colonoscopy is of major importance, as it is associated with a reduction in both crc incidence and mortality. in france, the institut national du cancer (inca) recommends colonoscopy with indigo carmine chromoendoscopy (ce), as it is associated with a significant increase in the adenoma detection rate (adr) compared with white light. however, ec is not routinely performed in clinical practice, as it is a time-consuming technique requiring a dedicated slot with a trained operator. recent years have seen the emergence of artificial intelligence techniques for real-time polyp detection aids or cade devices. these easy-to-use systems have shown very promising results compared with high-definition (hd) white light. indeed, data from the first meta-analysis of 5 randomized controlled trials (4354 patients) confirmed a significantly higher add in the cade group than in the hd group (36.6% vs. 25.2%; 95% ci\], 1.27-1.62; p \ 95%) and characterization of colonic polyps in real time. to date, artificial intelligence has never been evaluated for crc screening in patients followed up for ls. the aim of this work is to evaluate the effectiveness of the cad eye system in this specific population. to this end, we intend to conduct a randomized, controlled, non-inferiority trial comparing cad eye with ce in patients with ls.


Eligibility criteria:
inclusion criteria: * confirmed pathogenic mutation (path_mlh1, path_msh2, path_msh6, path_pms2, path_epcam) * male or female of legal age at time of colonoscopy prescription. * patient agreeing to participate in the study * person affiliated with or benefiting from a social security scheme * free, informed and express consent exclusion criteria: * patient undergoing total colectomy with ileoanal or ileosigmoid anastomosis * patient with a history of crohn's disease or ulcerative colitis * patients with a known allergy or intolerance to polyethylene glycol and ascorbic acid. * patients unable to undergo fractionated colonic preparation * inadequate colonic preparation: boston sub-score \<2 per segment * patient under guardianship or protected person * patient who does not understand french or cannot read * person not affiliated to a social security system. * pregnant women

Keywords: lynch syndrome cad eye adenoma detection rate colorectal screening artificial intelligence
safety and efficacy of connecting the residual ear to the cartilage scaffold in first- vs. second-stage surgery

Conditions: Microtia; Outcome Assessment; RCT; Surgery Related Complications Rate; Treatment Outcome; Reconstruction

Summary: eligible patients will be admitted from the outpatient clinic to complete the relevant examinations after admission（preoperative routine examination and chest ct）. the baseline parameters will be registered when admitted to hospital, including case number, diagnosis, sex, age, height, weight, and underlying medical conditions. patients have at least 12 hours to consider participation in the study and will be given the opportunity to ask questions about the study. written informed consent will be obtained by the surgical resident or the surgeon after admission to the hospital. randomization will be done by relevant member . after inclusion, patients will be allocated to one of the two study groups (first-stage connection or second-stage connection) using an online randomization program. the perioperative care will be the same for all included patients.surgery will be performed by experienced surgeons, with non-expanded ear reconstruction using autologous rib cartilage. the surgery normally comprises two stages. after each surgery, details and duration of the surgery will be documented. for each stage of surgery, patients are scheduled for visits about 3-6 months. in addition, after the total surgery, patients are to fill out 'glasgow benefit inventory' and 'patient and observer scar assessment scale'.


Eligibility criteria:
inclusion criteria: all consecutive patients between 6 and 30 years with a congenital concha-microtia8, admitted to our hospital are potentially eligible, and enrollment in the study will be based on the following criteria. 1. patients were fully informed about the purpose, modalities and risks associated with this study, signed an informed consent form and were willing to be followed up. 2. contrast-enhanced computed tomography (ct) scan shows he or she has 3.patients can tolerate general anesthesia without severe chronic organic or mental illness. exclusion criteria: 1. patients combined with other ear diseases such as ear fistula, titis media, etc. 2. patients receive other unrelated ear surgeries during the study 3. skin in the surgical area with infection, ulceration, and scarring.
a study of kw-6356 in subjects with early parkinson's disease

Conditions: Parkinson's Disease

Summary: the primary objective is to evaluate the effect of kw-6356 on motor symptoms in parkinson's disease and the primary endpoint is the change from baseline in the mds-updrs part iii score between kw-6356 and placebo in subjects with early parkinson's disease in japan.


Eligibility criteria:
inclusion criteria: * subject fulfills the uk parkinson's disease society brain bank clinical diagnostic criteria * parkinson's disease patients in stages 1 to 3 on the modified hoehn and yahr scale * mds-updrs part iii score of ≥ 15 exclusion criteria: * use of any cyp3a4/5-related drugs within 2 weeks prior to enrollment. * use of any of the specified antiparkinsonian drugs and dopamine antagonists during the specified period. * treatment with levodopa/dci at any time in the past for a period of 4 weeks or more. * neurosurgical operation for parkinson's disease (stereotactic surgery, deep brain stimulation or gamma knife), or treatment by transcranial magnetic stimulation (tms). * either of the following criteria consecutively at screening and enrollment; * resting pulse \> 100 bpm * resting systolic blood pressure \> 140 mmhg, or diastolic blood pressure \> 90 mmhg * significant dementia or a mini-mental state examination (mmse) score of ≤ 23. * subject has a history or evidence of suicidal ideation (severity of 4 or 5) or any suicidal behavior based on an assessment with the columbia-suicide severity rating scale (c-ssrs) at baseline. * anyone otherwise considered unsuitable for the study by the investigator or sub-investigator including those who are unable to communicate or to cooperate with the investigator or sub-investigator.
the effect of a lumbar rotational spinal mobilization technique with lumbar disc herniation

Conditions: Lumbar Disc Herniation

Summary: the aim of this study was to research the effect of the lumbar spinal rotational mobilization technique on radiological findings, pain, disability and joint range of motion (rom) in patients with lumbar disc herniation

in our study, it was aimed to investigate the acute effect of lumbar rotational spinal mobilization technique on radiological findings, pain, disability and range of motion in 26 patients diagnosed with lumbar disc herniation(ldh) by magnetic resonance imaging(mri) and physical examination. disc height, herniation distance and facet joint distance of the patients were measured with mri. pain was assessed with the visual analogue scale. disability was measured with the oswestry low back pain disability questionnaire and lumbar range of motion(rom) was measured with a goniometer and tape measure. rotational spinal mobilization technique was applied to the patients in 2 sessions with a one-week interval, slowly and with 30 repetitions in both directions. all assessments were repeated within 1 week after treatment. it was observed whether there was an improvement in terms of radiological, pain, disability and rom in the patients. 2 months after the 2nd evaluation, other parameters except the radiological evaluation were reapplied and it was tried to determine whether the effect persisted.

Eligibility criteria:
inclusion criteria: * being diagnosed with ldh by mri and physical examination * having pain due to ldh * be between the ages of 18 and 65 exclusion criteria: * history of spinal surgery * history of autoimmune disease (ankylosing spondylitis, rheumatoid arthritis or other disease) * spondylolysis or spondylolisthesis * spinal fracture * cardiac pathology * stroke history * cauda equina syndrome, * continuous painkiller drug use * spinal inflammation * spinal tumor * corticosteroid drug use i̇n the last month * osteoporosis

Keywords: lumbar disc herniation manual therapy lumbar spinal rotational mobilization
daily versus alternate day plasma exchange in wilson disease with acute liver failure in children

Conditions: Acute Liver Failure; Wilson Disease

Summary: wilson disease in children has a varied presentation. wilson disease with acute liver failure is associated with very high mortality and morbidity. the standard therapy i.e chelation (with either d- penicillamine or trientene can be used as a temporizing agent to treat the enormous release of copper into the blood stream; however, substantial removal is not achieved for at least 1 to 3 months. plasma exchange provides a means of rapid means of removal of copper. as per american society for apheresis, tpe in wilson disease with acute liver failure can rapidly remove an average of 20 mg of copper per tpe treatment. decreased serum copper may decrease hemolysis, prevent progression of kidney failure and provide clinical stabilization. tpe can also remove large molecular weight toxins (aromatic amino acids, ammonia, endotoxins) and other factors, which may be responsible for hepatic coma. the frequency of said tpe is not defined as most evidence is based on case reports and case series. copper is highly protein bound and the volume of distribution for copper is large. under normal conditions, 90-95% of serum copper is ceruloplasmin-bound with the remaining 5-10% being nonceruloplasmin-bound. tpe efficiently removes both ceruloplasmin- and albumin-bound copper. ffp used for exchange can be helpful in treating the associated coagulopathy. tpe has been used as a bridge to liver transplantation as well as seen to improve survival with native liver, the optimum protocol for same remains uncertain.

study population: children aged 3 to 18 years with wilson disease (diagnosed as per leipzig score \>=4) with fulminant presentation (as defined by new wilson index\>= 11 and inr \>= 2.5 ). adverse effects: therapeutic plasma exchange has been shown to be safe and effective in improving native liver survival in wilson disease patients and is currently standard of care in patients with wilson disease with acute liver failure. however, tpe can be associated with risk of adverse events like infections, fluid overload or circulatory insufficiency, hypersensitivity to blood products. stopping rule: 1. septic shock 2. anaphylaxis to blood products 3. he grade3/4 4. inr \> 5 any time point 5. inr \>3.5 24 hours after 3 hvp patients fulfilling criteria 3, 4 and 5 would be listed for liver transplantation. in case of 1, 2 appropriate medical management will be done as per department protocol. intervention: group 1: daily plasma exchange + smt (maximum 3+1 sessions during a period of 7 days) group 2: alternate day therapeutic plasma exchange + smt

Eligibility criteria:
inclusion criteria: 1. wilson disease with new wilson index of ≥ 11 and inr ≥ 2.5 2. children aged 3 years to 18 years exclusion criteria: 1. grade 3 or grade 4 hepatic encephalopathy 2. septic shock 3. disseminated intravascular coagulation 4. marked hemodynamic instability requiring a high dose of vasopressors (norepinephrine \>0.5 mcg/kg/min) 5. any severe cardio-pulmonary pre-existing disease
integrating insulin delivery and glucose sensing in subcutaneous tissue for the treatment of type-1 diabetic patients

Conditions: Type 1 Diabetes

Summary: the study seeks to use microdialysis and microperfusion techniques to assess the feasibility of combining insulin delivery and glucose sensing at a single subcutaneous tissue site.

current treatment of in type 1 diabetes comprises the measurement of glucose in capillary blood obtained by fingersticking and administration of exogenous insulin in the form of a subcutaneous bolus injection or subcutaneous infusion. this treatment could be simplified if there were a stable ratio between blood glucose concentration and tissue glucose level at the site of insulin delivery so that tissue glucose levels could be used to estimate blood glucose levels, thereby circumventing the need for fingerstick blood glucose monitoring. the aim of this study is to ascertain whether a stable ratio between the blood glucose concentration and the glucose levels at the tissue site of insulin infusion exists when this tissue site is exposed to variable insulin infusion rates. to achieve this, microdialysis and microperfusion probes are applied in healthy and type 1 diabetic subjects to perform insulin delivery and glucose sampling at the same adipose tissue site during euglycemic clamps and oral glucose tolerance tests.

Eligibility criteria:
inclusion criteria: * type 1 diabetes mellitus patients aged 18 - 65 * healthy subjects aged 18 - 65 * informed consent obtained before any trial-related activities. diabetic subjects: * c-peptide negative (≤ 0.05 nmol/l) * hba1c (glycosylated haemoglobin a1c) \< 10% exclusion criteria: * severe diabetic complications (e.g., proliferative retinopathy, severe nephropathy) * female of childbearing potential who is pregnant, breast-feeding or intends to become pregnant or is not using adequate contraceptive methods * subject with mental incapacity or language barriers
critical respiratory diseases in ex-preterm infants in picu

Conditions: Infant, Premature, Diseases; Respiratory Disease; Respiratory Failure; Premature Birth

Summary: premature birth is the leading cause of death in children younger than 5 years old worldwide, especially in low- and middle-income countries. premature infants who survive are at greater risk of a range of short-term and long-term health consequences. common long-term health morbidities among children who are born prematurely include cerebral palsy, infections (particularly respiratory infections), bronchopulmonary dysplasia, feeding difficulties, hypoxic-ischemic encephalopathy, visual and hearing problems. re-hospitalization occurs frequently during first few years of life among ex-premature infants with respiratory illness. this leads to increased financial burden for health care system and families. the impact of prematurity on the health care system, especially on pediatric intensive care units (picus) has mainly been evaluated in high income countries. little is known about long term health outcomes of ex-premature infants and their impact on the cost to health care system in low- and middle-income countries. this pilot, single institution, observational study aims to determine the prevalence, course of the diseases, and outcomes of ex-premature infants with respiratory illnesses who are admitted to a picu of a tertiary children's hospital in vietnam. investigators will determine the epidemiology of respiratory illness, and the resource utilization for these children in the picu. to achieve these aims, the investigators will prospectively screen and recruit all children aged less than 2 years old admitted to the picu with respiratory illness/failure and collect pertinent clinical data. the study participants will be follow-up until picu discharge.


Eligibility criteria:
inclusion criteria: * all patients aged ≤ 2 year olds with respiratory diseases admitted to pediatric intensive care unit of vietnam national children's hospital exclusion criteria: * nil

Keywords: respiratory diseases, ex-prematurity respiratory failure pediatric intensive care
first study in humans with gsk424887

Conditions: Depressive Disorder and Anxiety Disorders

Summary: this is the first study in humans with gsk424887 to evaluate what effects, good or bad, the drug has on human health (safety and tolerability) and the amount of drug which gets into the bloodstream and is eliminated from the body (pharmacokinetics). also the study aims to investigate the penetration of the drug in the human brain by using pet (positron emission tomography) imaging technology


Eligibility criteria:
inclusion criteria: * healthy males aged 18-45 years, limited to 25-40 years for pet section exclusion criteria: * the subject has a positive: drug/alcohol, hepatitis, hiv screen * the subject has a history of psychiatric illness suicidal attempts or behaviour. * abuse of alcohol. * clinically significant laboratory, ecg abnormality; * the subject has recently received an investigational. * use of prescription or non-prescription drugs, * history or presence of allergy to the study drug or drugs of this class,. * donation of more than 500 ml blood within the 90 days before dosing. * an unwillingness of male subjects to comply with contraceptive requirements * average daily caffeine intake exceeding protocol requirements.

Keywords: nk1 antagonist and ssri healthy subjects safety first time in human
high-intensity functional circuit training and cognitive function

Conditions: Exercise; Cognition

Summary: the study investigates the acute effects of one bout of high-intensity functional circuit training on cognitive function against no-activity control and aerobic exercise.

exercise has been shown to acutely improve cognitive function (cf). however, it is unknown as to how high-intensity functional circuit training (hifct) affects cf. this study aims to compare the acute effects of one hifct bout against an inactive control condition as well as against one bout of conventional aerobic exercise. healthy participants will be randomly allocated to either a hifct group, an aerobic exercise group (walking) or an inactive control group. in the hifct group, participants perform a 15-minute workout, which is composed of functional exercise mimicking activities of daily living (e.g. squat, step-ups) and conducted in a circuit format. each exercise is performed at all-out intensity for 20 seconds, followed by a 10-second break. thus, the 15-min workout consists of 30 exercise intervals. in the control group, participants will be inactively seated for 15 minutes, reading sports brochures and literature. in the walking group, participants will walk at moderate intensity on a treadmill for 15 minutes. outcomes assessed pre and post-workout include the stroop test, trail making test, stop-signal task, heart rate, subjective arousal, rate of perceived exertion and exercise enjoyment.

Eligibility criteria:
inclusion criteria: * 18-40 years exclusion criteria: * severe orthopaedic, psychiatric, neurological, endocrine or cardiovascular disorders * acute illness, not completely healed injuries * muscle soreness * pregnancy/nursing period
simultaneous resection of pancreatic cancer and liver oligometastasis after induction chemotherapy

Conditions: Pancreatic Cancer; Liver Metastases; Surgery

Summary: this study is a multi-center phase 3 trial to evaluate a treatment strategy for selecting patients who can benefit from the synchronous resection of primary pancreatic cancer and liver oligometastasis after induction chemotherapy. half of participants who meet the entry criterion will receive surgical intervention, while the other half will continue to receive standard chemotherapy.


Eligibility criteria:
note: this study has two steps. in the first step, patients who meet the criteria for candidates will receive standard first-line chemotherapy for pancreatic cancer. response evaluation criteria in solid tumors (recist) criteria was employed to measure tumor's response to chemotherapy every two cycles. until some of them meet the criteria for intervention, they will be randomized and receive relevant interventions. inclusion criteria for candidates: 1. voluntary participation 2. 18-75 years old 3. eastern cooperative oncology group (ecog) 0-1 4. stage iv pancreatic cancer with no more than 3 liver metastases 5. histologically confirmed diagnosis of pancreatic cancer 6. no contraindication of chemotherapy exclusion criteria for candidates: 1. not want to receive chemotherapy or potential operation. 2. metastases at other sites except for liver 3. with other malignancies 4. receive chemotherapy, radiotherapy, and interventional therapy before 5. contraindication of potential operation inclusion criteria for intervention: 1. primary tumor and liver metastatic sites are both resectable. 2. no new metastatic sites were observed 3. abnormal serum tumor maker levels decreased by more than 50% after chemotherapy. in the serum tumor makers, carbohydrate antigen 19-9 (ca19-9) was always the first choice for evaluation and it should be below 500u/l after treatment. however, when the baseline ca19-9 was within the normal range, carbohydrate antigen 125 (ca125) and carcinoembryonic antigen (cea) were the alternative candidate indicators. exclusion criteria for intervention: 1. contraindication of operation
a multicentric cohort of autoimmune encephalitis

Conditions: Autoimmune Encephalitis

Summary: this study aims to establish an autoimmune encephalitis cohort and observe the prognosis of patients with different subtypes and subgroups (e.g. epilepsy subgroup and teratoma subgroup ). clinical characteristics, biological samples, and imaging data will be collected to discover blood and imaging biomarkers for providing support for the treatment, early warning, and outcome prediction.


Eligibility criteria:
inclusion criteria: * 1. gender and age are not limited; 2. newly diagnosed autoimmune encephalitis according to at least one of the following three criteria: 1. according to the criteria of graus et al in 2016, diagnosed as "definite autoimmune limbic encephalitis" 2. according to the criteria of graus et al in 2016, diagnosed as "possible autoimmune encephalitis" and typical autoantibodies are detected in serum or cerebrospinal fluid 3. according to the criteria of graus et al in 2021, diagnosed as "possible or definite paraneoplastic neurological syndrome" (excluding peripheral nervous system syndrome) 3. the patient or legal representative voluntarily signed the paper informed consent form. additional inclusion criteria for patients in the epilepsy subgroup: patients diagnosed with epilepsy secondary to autoimmune encephalitis. exclusion criteria: * no additional exclusion criteria